Chemotherapy and immunotherapy: mapping the road ahead

被引：106

作者：

Cook, Alistair M. ^{[1
,2
]}

Lesterhuis, W. Joost ^{[1
,2
]}

Nowak, Anna K. ^{[1
,2
,3
]}

Lake, Richard A. ^{[1
,2
]}

机构：

[1] Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia

[2] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia

[3] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA, Australia

来源：

CURRENT OPINION IN IMMUNOLOGY | 2016年 / 39卷

关键词：

IMMUNOGENIC CELL-DEATH; REGULATORY T-CELLS; CTLA-4; BLOCKADE; ANTICANCER CHEMOTHERAPY; CHRONIC INFLAMMATION; CHECKPOINT BLOCKADE; NIVOLUMAB ANTI-PD-1; CROSS-PRESENTATION; SUPPRESSOR-CELLS; IMMUNE-SYSTEM;

D O I：

10.1016/j.coi.2015.12.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cancer immunotherapy, and in particular checkpoint blockade, is now standard clinical care for a growing number of cancers. Cytotoxic drugs have been the primary weapon against cancer for a long time and have typically been understood because of their capacity to directly kill tumour cells. It is now clear that these drugs are potential partners for checkpoint blockade and different drugs can influence the immune response to cancer through a wide variety of mechanisms. Some of these relate to immunogenic cell death, whilst others relate to changes in antigen-presentation, tumour cell targeting, or depletion of immunosuppressive cells. Here, we review some recent advances in our understanding of the immunological changes associated with chemotherapy, discuss progress in combining chemotherapy with checkpoint blockade, and comment on the difficulties encountered in translating promising preclinical data into successful treatments for cancer patients.

引用

页码：23 / 29

页数：7

共 55 条

[1] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC) [J].

Antonia, S. J. ;

Brahmer, J. R. ;

Gettinger, S. ;

Chow, L. Q. ;

Juergens, R. ;

Shepherd, F. A. ;

Laurie, S. A. ;

Gerber, D. E. ;

Goldman, J. ;

Shen, Y. ;

Harbison, C. ;

Chen, A. C. ;

Borghaei, H. ;

Rizvi, N. A. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 :S2-S2

[2] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[3] Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed? [J].

Aston, Wayne J. ;

Fisher, Scott A. ;

Khong, Andrea ;

Mok, Clara ;

Nowak, Anna K. ;

Lake, Richard A. ;

Lesterhuis, W. Joost .

LUNG CANCER MANAGEMENT, 2014, 3 (06) :443-457

[4] A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma [J].

Beatty, Gregory L. ;

Torigian, Drew A. ;

Chiorean, E. Gabriela ;

Saboury, Babak ;

Brothers, Alex ;

Alavi, Abass ;

Troxel, Andrea B. ;

Sun, Weijing ;

Teitelbaum, Ursina R. ;

Vonderheide, Robert H. ;

O'Dwyer, Peter J. .

CLINICAL CANCER RESEARCH, 2013, 19 (22) :6286-6295

[5] Combinatorial strategies for the induction of immunogenic cell death [J].

Bezu, Lucillia ;

Gomes-de-Silva, Ligia C. ;

Dewitte, Heleen ;

Breckpot, Karine ;

Fucikova, Jitka ;

Spisek, Radek ;

Galluzzi, Lorenzo ;

Kepp, Oliver ;

Kroemer, Guido .

FRONTIERS IN IMMUNOLOGY, 2015, 6

[6] Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth [J].

Bruchard, Melanie ;

Mignot, Gregoire ;

Derangere, Valentin ;

Chalmin, Fanny ;

Chevriaux, Angelique ;

Vegran, Frederique ;

Boireau, Wilfrid ;

Simon, Benoit ;

Ryffel, Bernhard ;

Connat, Jean Louis ;

Kanellopoulos, Jean ;

Martin, Francois ;

Rebe, Cedric ;

Apetoh, Lionel ;

Ghiringhelli, Francois .

NATURE MEDICINE, 2013, 19 (01) :57-64

[7] Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death [J].

Casares, N ;

Pequignot, MO ;

Tesniere, A ;

Ghiringhelli, F ;

Roux, S ;

Chaput, N ;

Schmitt, E ;

Hamai, A ;

Hervas-Stubbs, S ;

Obeid, M ;

Coutant, F ;

Métivier, D ;

Pichard, E ;

Aucouturier, P ;

Pierron, G ;

Garrido, C ;

Zitvogel, L ;

Kroemer, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) :1691-1701

[8] Chemoimmunotherapy: reengineering tumor immunity [J].

Chen, Gang ;

Emens, Leisha A. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (02) :203-216

[9] Effective Chemoimmunotherapy with Anti-TGFβ Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer [J].

Chen, Xin ;

Yang, Yuan ;

Zhou, Qiong ;

Weiss, Jonathan M. ;

Howard, OlaMae Zack ;

McPherson, John M. ;

Wakefield, Lalage M. ;

Oppenheim, Joost J. .

PLOS ONE, 2014, 9 (01)

[10] Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system [J].

Ciampricotti, Metamia ;

Hau, Cheei-Sing ;

Doornebal, Chris W. ;

Jonkers, Jos ;

de Visser, Karin E. .

NATURE MEDICINE, 2012, 18 (03) :344-346

← 1 2 3 4 5 6 →